MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.320
+0.040
+1.22%
After Hours: 3.300 -0.02 -0.60% 18:25 01/24 EST
OPEN
3.150
PREV CLOSE
3.280
HIGH
3.340
LOW
2.870
VOLUME
15.68M
TURNOVER
--
52 WEEK HIGH
18.77
52 WEEK LOW
1.400
MARKET CAP
661.30M
P/E (TTM)
-13.4413
1D
5D
1M
3M
1Y
5Y
Ocugen, Inc. (NASDAQ:OCGN) Could Be Less Than A Year Away From Profitability
Ocugen, Inc. ( NASDAQ:OCGN ) is possibly approaching a major achievement in its business, so we would like to shine...
Simply Wall St. · 8h ago
Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety
Nirdosh Jagota, PhD joins Ocugen, Inc. Ocugen, Inc. is pleased to welcome Nirdosh Jagota, PhD, Senior Vice President, Regulatory Affairs, Compliance & Safety. He brings 30 years of experience in leading roles in drug development and regulatory sciences for...
GlobeNewswire · 11h ago
Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19,...
GlobeNewswire · 3d ago
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Benzinga · 4d ago
In Search of a Better Covid Vaccine, This Analyst Taps Ocugen
When it comes to Covid-19 vaccines, Pfizer (PFE) and Moderna (MRNA) get all the headlines. To an extent, that makes sense. After all, both Pfizer's Comirnaty Covid vaccine and Moderna's Spikevax use mRNA technology to elicit an immune response without ever...
TipRanks · 01/14 16:19
Gen Z investors shift focus from 'meme-stocks' to the 'metaverse,' report shows
reuters.com · 01/14 14:00
Ocugen's (OCGN) COVID-19 Booster Effective Against Omicron
Ocugen's (OCGN) India-based partner announces robust neutralizing antibody responses against Omicron and Delta variants, following the administration of the booster dose of COVID-19 vaccine, Covaxin.
Zacks · 01/13 15:29
Looking Into Ocugen Inc's Recent Short Interest
Ocugen Inc's (NASDAQ:OCGN) short percent of float has risen 9.83% since last its last report. The company recently reported that it has 54.30 million shares sold short, which is 27.83% of all regular shares that are available for trading.
Benzinga · 01/12 18:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCGN. Analyze the recent business situations of Ocugen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
50.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OCGN stock price target is 8.88 with a high estimate of 15.00 and a low estimate of 4.500.
High15.00
Average8.88
Low4.500
Current 3.320
EPS
Actual
Estimate
0.020.170.320.46
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 133
Institutional Holdings: 60.94M
% Owned: 30.59%
Shares Outstanding: 199.19M
TypeInstitutionsShares
Increased
42
4.27M
New
20
229.71K
Decreased
28
5.04M
Sold Out
30
937.49K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Chairman/Chief Executive Officer/Director
Shankar Musunuri
Chief Financial Officer/Secretary
Sanjay Subramanian
Senior Vice President
Vijay Tammara
Independent Director
Kirsten Castillo
Independent Director
Prabhavathi Fernandes
Independent Director
Uday Kompella
Independent Director
Ramesh Kumar
Independent Director
Manish Potti
Independent Director
Junge Zhang
No Data
About OCGN
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine is developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a novel biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Webull offers kinds of Ocugen Inc stock information, including NASDAQ:OCGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCGN stock methods without spending real money on the virtual paper trading platform.